# Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Source: https://onco.cc/trials/nct06088290/  
OnCo record `nct06088290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Lurbinectedin and Doxorubicin in uterine sarcoma, run by PharmaMar, active and no longer recruiting.

## Summary

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) is a phase 3 interventional study registered as NCT06088290 by PharmaMar, with 469 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2029-08-30. Interventions recorded: Lurbinectedin and Doxorubicin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06088290
- Phase: 3
- Setting: Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
- Sponsor: PharmaMar
- Enrolled: 469

## Sources

- ClinicalTrials.gov NCT06088290: https://clinicaltrials.gov/study/NCT06088290

## Connected records

- cancers: [Uterine sarcoma](https://onco.cc/cancers/uterine-sarcoma/)
- drugs: [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Lurbinectedin](https://onco.cc/drugs/lurbinectedin/)
- companies: [PharmaMar](https://onco.cc/companies/pharmamar/)

---
JSON: https://onco.cc/api/v1/entities/nct06088290.json